WinstonWınston
FormFactor logo

FormFactor

FORM
53
Semiconductors · Technology
Price
$105.57
-1.54 (-1.44%)
Market Cap
$8.23B
Exchange
NASDAQ
Winston Score
53
Winston is curious
Mixed quality — meaningful strengths and weaknesses.

Share count falling — buybacks

1.0% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 79.1M (2021) → 78.3M (2025)

FormFactor, Inc. designs, manufactures, and sells probe cards, analytical probes, probe stations, metrology systems, thermal systems, and cryogenic systems to semiconductor companies and scientific institutions. It operates in two segments, Probe Cards and Systems. The company offers probe cards to test various semiconductor device types, including systems on a chip products, mobile application processors, microprocessors, microcontrollers, and graphic processors, as well as radio frequency, ana

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+32.0% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+214.0% YoY

YoY Growth Rate

Strong earnings growth

R&D Spend

$116M/ year

Flat (-5% vs prior year)

14.8% of revenue

In line with sector average (15%)

Steady R&D investment year-over-year

Insider Activity

0.8%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$124M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

FormFactor grew revenue 32% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
47.9%
Healthy — 47.9% gross margin
Operating Margin
20.8%
Excellent — 20.8% operating margin
ROCE
4.4%
Weak — 4.4% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+9.6%
Steady sales growth (9.6% YoY)
EPS YoY
+25.2%
Earnings growing fast (25.2% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
200%
Turns 200% of profit into real cash
FCF Margin
4.4%
Thin free cash flow (4.4%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.02
Conservative — low debt load (0.02)
Interest Cover
252.69x
Comfortably covers interest (252.7x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
120.0x
Expensive — P/E 120.0

P/E over 35. The market is pricing in heavy, sustained growth.

P/E vs Forward
+72.1
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (120.0 → 47.9)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial